After a 5‑day course of Zerbaxa (ceftolozane/tazobactam) for an ESBL‑producing urinary tract infection, can a single dose of fosfomycin be given?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can You Give Fosfomycin After Zerbaxa for ESBL UTI?

Yes, you can give a single dose of oral fosfomycin after completing a 5-day course of Zerbaxa for an ESBL UTI, but only if the patient still has residual symptoms or if you're using it as oral step-down therapy to complete the treatment course.

Clinical Context and Rationale

The key question here is whether you're adding fosfomycin as:

  1. Step-down/transition therapy to complete the treatment course
  2. Additional treatment for persistent symptoms
  3. Prophylaxis (not indicated)

If Using as Step-Down Therapy

This is supported by high-quality evidence. A 2026 multicenter RCT demonstrated that oral fosfomycin (3g once daily) was noninferior to continued IV therapy when used as oral transition therapy after 3-7 days of IV antibiotics for ESBL-producing Enterobacterales complicated UTIs 1. The study showed:

  • Clinical cure: 92.8% with oral fosfomycin vs 95.2% with continued IV therapy
  • Microbiological cure: 98.0% vs 96.6%
  • Comparable 30-day outcomes

However, note the dosing difference: The evidence supports daily dosing of fosfomycin 3g (not the traditional single-dose regimen) when used for ESBL infections. A 2016 study showed common effective regimens were fosfomycin 3g every 72 hours (62% of cases) or every 48 hours (23% of cases) for outpatient ESBL UTI treatment 2.

Standard Treatment Duration Considerations

According to current guidelines, the recommended duration for complicated UTI treatment is 7 days 3, 4. Your 5-day Zerbaxa course is shorter than guideline recommendations. The FDA label for Zerbaxa specifies 7 days for cUTI including pyelonephritis 5.

Specific Recommendations

If the patient has improved after 5 days of Zerbaxa:

  • Consider extending treatment to complete a 7-day course using oral fosfomycin 3g every 48-72 hours (not just a single dose)
  • A single dose of fosfomycin alone would be insufficient for completing therapy for complicated UTI/ESBL infection

If symptoms persist after 5 days:

  • Obtain repeat urine culture before adding fosfomycin
  • Consider that the organism may not be susceptible to the original agent 3
  • Fosfomycin 3g can be given, but use a multi-dose regimen (every 48-72 hours) rather than single-dose

If the patient is clinically cured after 5 days:

  • No additional antibiotics are needed
  • Routine post-treatment cultures are not indicated for asymptomatic patients 3

Important Caveats

  • Single-dose fosfomycin (3g once) is only recommended for uncomplicated cystitis in women 3, 4, not for ESBL complicated UTIs
  • For ESBL infections requiring oral therapy, fosfomycin should be dosed more frequently (every 24-48 hours) for adequate treatment 6
  • The traditional "one-and-done" fosfomycin dosing does not apply to complicated UTIs or ESBL infections
  • Consider that your 5-day course may be suboptimal; standard duration is 7 days for cUTI 3, 4, 5

Bottom line: Don't give just one dose of fosfomycin. Either extend to complete a proper 7-day course with multi-dose fosfomycin (3g every 48-72h for 2 more days), or if the patient is clinically well, stop antibiotics entirely.

References

Related Questions

In a female patient with an ESBL‑producing urinary tract infection who has completed a 5‑day course of Zerbaxa (ceftazidime/avibactam), should a single dose of fosfomycin be given and used as prophylaxis upon discharge?
What is the recommended duration of fosfomycin therapy for infections caused by extended‑spectrum β‑lactamase (ESBL)‑producing organisms?
What is the appropriate fosfomycin treatment regimen for a urinary tract infection with ESBL‑producing Escherichia coli that is susceptible to fosfomycin?
What is the appropriate antibiotic regimen for an infection caused by an ESBL-negative Enterobacteriaceae?
What oral antibiotic regimen is recommended for a male cancer patient with a complicated urinary tract infection?
How should a 34-year-old man with incidentally discovered hypertension, impaired renal function (serum creatinine ~2 mg/dL), proteinuria ~1.4 g/24 h, and renal biopsy showing thrombotic microangiopathy, but normal hemoglobin and platelet count, be managed?
What prophylactic regimen should be given to healthcare workers after direct skin contact with a patient with crusted (Norwegian) scabies?
How should I manage a 7‑year‑old child with recurrent brucellosis (Brucella abortus serology 1:360, Brucella melitensis negative, blood cultures negative) after a prior episode 3 months ago with a titre of 1:600 that was treated?
In a 9‑day‑old neonate with a harsh holosystolic murmur heard at the upper left and right sternal borders, radiating to the apex and both axillae, and with feeding difficulty and fatigue, what is the most likely diagnosis?
In a 115‑kg patient with an eGFR of 36 mL/min/1.73 m² who is already receiving vancomycin, meropenem, and moxifloxacin, are there any other combination considerations when adding tigecycline?
Do alprazolam (Xanax) and paroxetine (Paxera) cause constipation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.